All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention Multicenter Randomized PRAGUE-18 Study

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10329604" target="_blank" >RIV/00064165:_____/16:10329604 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/16:00093173 RIV/00216208:11110/16:10329604 RIV/00216208:11140/16:10329604 RIV/00216208:11150/16:10329604 and 4 more

  • Result on the web

    <a href="http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024823" target="_blank" >http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024823</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024823" target="_blank" >10.1161/CIRCULATIONAHA.116.024823</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention Multicenter Randomized PRAGUE-18 Study

  • Original language description

    Background: No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these newer P2Y12 inhibitors were first demonstrated relative to clopidogrel. Methods: This academic study was designed to compare the efficacy and safety of prasugrel and ticagrelor in acute myocardial infarction treated with primary or immediate percutaneous coronary intervention. A total of 1230 patients were randomly assigned across 14 sites to either prasugrel or ticagrelor, which was initiated before percutaneous coronary intervention. Nearly 4% were in cardiogenic shock, and 5.2% were on mechanical ventilation. The primary end point was defined as death, reinfarction, urgent target vessel revascularization, stroke, or serious bleeding requiring transfusion or prolonging hospitalization at 7 days (to reflect primarily the in-hospital phase). This analysis presents data from the first 30 days (key secondary end point). The total follow-up will be 1 year for all patients and will be completed in 2017.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Circulation

  • ISSN

    0009-7322

  • e-ISSN

  • Volume of the periodical

    134

  • Issue of the periodical within the volume

    21

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    37

  • Pages from-to

    1603-1612

  • UT code for WoS article

    000388466500009

  • EID of the result in the Scopus database

    2-s2.0-84996553455